Optimizing first-line NALIRIFOX and exploring the role of the microbiota in second-line pancreatic cancer treatment: the PRODIGE 105-GERCOR 116 PANORAMIX trial

Digestive and Liver Disease · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles